Τόμος 24 (2006) – Τεύχος 2 – Άρθρο 1 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 24 (2006) – Issue 2 – Article 1 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Υβόννη Δημουλά, Χριστίνα Μαρβάκη, Βαρβάρα Σοπίδου, Αναστασία Κανέλλου

Γενικό Τμήμα Βασικών Ιατρικών Μαθημάτων και Τμήμα Νοσηλευτικής Α, Σχολή Επιστημών Υγείας και  Πρόνοιας, Τεχνολογικό Εκπαιδευτικό Ίδρυμα (ΤΕΙ) Αθήνας, Αθήνα, Ελλάδα

Y. Dimoula, Ch. Marvaki, Β. Sopidou, A. Kanellou

Faculty of Health and Caring Professions, Tech­nological Educa­tional Institution (TEI) of Athens, Athens, Hellas

2. Panagis G., Kastellakis A.: The endocannabinoid sys­tem: new prospects in therapeutics. Epitheor. Klin. Farma­kol. Farmakokinet. Greek Edition 24: 73-89 (2006)

3. Gaoni Y., Mechoulam R.: Isolation,structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86: 1646-1647 (1964)

4. Piomelli D.: The molecular logic of endocannabinoid signaling. Nat. Rev. Neurosci 4: 873-884 (2003)

5. De Petrocellis L., Cascio M.G., Di Marzo V.: The endo­cannabinoid system: a general view and latest additions. Br. J. Pharmacol. 141: 765-774 (2004)

6. Pagotto U., Pasquali R.: Fighting obesity and associated risk factors by antagonizing cannabinoid type 1 receptors. Lancet 365: 1363-1364 (2005)

7. Begg M., Pacher P., Batkai S., Osei-Hyiaman D., Of­fertaler L., Mo F.M., Liu J., Kunos G.: Evidence for novel cannabinoid receptors. Pharmacol. Ther. 106: 133-145 (2005)

8. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., De Costa B.R., Rice K.C.: Cannabinoid re­ceptor localization in brain. Proc. Natl. Acad. Sci. USA 87: 1932-1936 (1990)

9. Pagotto U., Marsicano G., Fezza F., Theodoropoulou M., Gruebler Y., Stalla J., Arzberger T., Milone A., Losa M., Di Marzo V., Lutz B., Stalla G.K.: Normal human pitui­tary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J. Clin. Endocrinol. Metab. 86: 2687-2696 (2001)

10. Howlett A.C., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., Pertwee R.G.: Interna­tional Union of Pharmacology. XXVII. Classification of cannabi­noid receptors. Pharmacol. Rev. 54: 161-202 (2002)

11. Ibrahim M.M., Porreca F., Lai J., Albrecht P.J., Rice F.L., Khodorova A, Davar G, Makriyannis A, Vanderah T.W., Mata H.P., Malan T.P.,Jr: CB2 cannabinoid receptor activation produces antinociception by stimulating periph­eral release of endogenous opioids. Proc. Natl. Acad. Sci. USA 102: 3093-3098 (2005).

12. Di Marzo V., Bifulco M., De Petrocellis L.: The endo­cannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov. 3: 771-784 (2004)

13. Di S., Malcher-Lopes R., Halmos K.C., Tasker J.G.: 2003 Nongenomic glucocorticoid inhibition via endocan­nabinoid release in the hypothalamus: a fast feedback mechanism. J. Neurosci. 23: 4850-4857 (2003)

14. Hanus L., Breuer A., Tchilibon S., Shiloah S., Golden­berg D., Horowitz M., Pertwee R.G., Ross R.A., Mechou­lam R., Fride E.: HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. USA 96: 14228-14233 (1999)

15. Pertwee R.G.: Inverse agonism and neutral antago­nism at cannabinoid CB1 receptors. Life Sci. 76: 1307-1324 (2005)

16. Bouaboula M., Perrachon S., Milligan L., Canat X., Rinaldi-Carmona M., Portier M., Barth F., Calandra B., Pecceu F., Lupker J., Maffrand J.P., Le Fur G., Casellas P.: A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase ac­tiva­tion stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem. 272: 22330-22339 (1997)

17. Williams C.M., Rogers P.J., Kirkham T.C.: Hyper­phagia in pre-fed rats following oral Δ⁹-THC. Physiol. Be­hav. 65: 343-346 (1998)

18. Greenberg I., Kuehnle J., Mendelson J.H., Bernstein J.G.: Effects of marihuana use on body weight and caloric intake in humans. Psychopharmacology (Berl.) 49: 79-84 (1976)

19. Foltin R.W., Brady J.V., Fischman M.W.: Behavioral analysis of marijuana effects on food intake in humans. Pharmacol. Biochem. Behav. 25: 577-582 (1986)

20. Cat L.K., Coleman R.L.: Treatment for HIV wasting syndrome. Ann. Pharmacother. 28: 595-597 (1994)

21. Beal J.E., Olson R., Lefkowitz L., Laubenstein L., Bellman P., Yangco B., Morales J.O., Murphy R., Powderly W., Plasse T.F., Mosdell K.W., Shepard K.V.: Long-term efficacy and safety of dronabinol for acquired immunodefi­ciency syndrome-associated anorexia. J. Pain Symptom Manage 14: 7-14 (1997)

22. Gorter R.W.: Cancer cachexia and cannabinoids. Forsch. Komplementarmed. 6 (Suppl 3): 21-22 (1999)

23. Sallan S.E., Zinberg N.E., Frei E.I.: 1975 Antiemetic effect of Δ⁹-tetrahydrocannabinol in patients receiving cancer chemotherapy. N. Engl. J. Med. 293: 795-797 (1975)

24. Volicer L., Stelly M., Morris J., McLaughlin J., Volicer B.J.: Effects of dronabinol on anorexia and disturbed be­havior in patients with Alzheimer’s disease. Int. J. Geriatr. Psychiatry 12: 913-919 (1997)

25. Williams C.M., Kirkham T.C.: Anandamide induces overeating: mediation by central cannabinoid (CB1) re­ceptors. Psychopharmacology (Berl) 143: 315-317 (1999)

26. Colombo G., Agabio R., Diaz G., Lobina C., Reali R., Gessa G.L.: Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci. 63: L113-L117 (1998)

27. Cota D., Marsicano G., Tschoep M., Gruebler Y., Flachskamm C., Schubert M., Auer D., Yassouridis A., Thone-Reineke C., Ortmann S., Tomassoni F., Cervino C., Nisoli E., Linthorst A.C., Pasquali R., Lutz B., Stalla G.K., Pagotto U.: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112: 423-431 (2003)

28. Ravinet-Trillou C., Delgorge C., Menet C., Arnone M., Soubrié P.: CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. Relat. Metab. Disord. 28: 640-648 (2004)

29. Bensaid M., Gary-Bobo M., Esclangon A., Maffrand J.P., Le Fur G., Oury-Donat F., Soubrié P.: The cannabi­noid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. 63: 908-914 (2003)

30. Jbilo O., Ravinet-Trillou C., Arnone M., Buisson I., Bribes E., Peleraux A., Penarier G., Soubrié P., Le Fur G., Galiegue S., Casellas P.: The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J. 19: 1567-1569 (2005)

31. Chandran M., Phillips S.A.,Ciaraldi T., Henry R.R.: Adiponectin: more than just another fat cell hormone? Diabetes Care 26: 2442-2450 (2003)

32. Poirier B., Bidouard J.P., Cadrouvele C., Marniquet X., Staels B., O’Connor S.E., Janiak P., Herbert J.M.: The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes. Metab. 7: 65-72 (2005)

33. Shearman L.P., Zhou D., Rosko K.M., Camacho R.E., Stribling D., MacIntyre D., Strack A.M.: Multiple day CB1R inverse agonist effects on hypothalamic gene expression and energy balance in diet-induced obese mice. Proc 34^th Annual Meeting of the Society for Neuroscience, San Diego, CA, (Abstract 76.4), 2004

34. Liu Y.L., Connoley I.P., Wilson C.A., Stock M.J.: Ef­fects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep (ob)/Lep(ob) mice. Int. J. Obes. Relat. Metab. Disord. 29: 183–187 (2005)

35. Osei-Hyiaman D., DePetrillo M., Pacher P., Liu J., Radaeva S., Batkai S., Harvey-White J., Mackie K., Offer­taler L., Wang L., Kunos G.: Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 115: 1298-1305 (2005)

36. Kola B., Hubina E., Tucci S.A., Kirkham T.C., Garcia E.A., Mitchell S.E., Williams L.M., Hawley S.A., Hardie D.G., Grossman A.B., Korbonits M.: Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J. Biol. Chem. 280: 25196-25201 (2005)

37. Gomez R, Navarro M, Ferrer B, Trigo JM,Bilbao A,Del Arco I,Cippitelli A,Nava F, Piomelli D, Rodriguez de Fonseca F 2002 A peripheral mechanism for CB1 can­nabinoid receptor-dependent modulation of feeding. J Neurosci 22:9612–9617

38. Engeli S., Bohnke J., Feldpausch M., Gorzelniak K., Janke J., Batkai S., Pacher P., Harvey-White J., Luft F.C., Sharma A M , Jordan J.: 2005 Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54: 2838-2843 (2005)

39. Van Gaal L.F., Rissanen A.M., Sceen A.J., Ziegler O., Rossner S.: Effects of the cannabinoid 1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1 year experience from the RIO-Europe study. Lancet 365: 1389-1397 (2005)

40. Després J.-P., Golay A., Larw Sjoström L. for the Ri­monabant in Obesity-Lipids Study Group: Effects of Ri­monabant on metabolic risk factors in overweight patients with dislipidemia. N. Egl. J. Med. 353: 2121-2134 (2005)